Picoprep Use In Pregnancy & Lactation

Pregnancy: There are no data with PICOPREP use in pregnant women to determine a drug-associated risk of adverse developmental outcomes.
In animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based on body surface area during organogenesis.
As picosulfate is a stimulant laxative, for safety measure, it is preferable to avoid the use of PICOPREP during pregnancy.
Breastfeeding: There is insufficient data on the use of PICOPREP in nursing mothers, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PICOPREP and any potential adverse effects on the breastfed infant from PICOPREP.
Fertility: Studies with PICOPREP in animals have shown no impairment of fertility or embryo-fetal toxicity. In studies with sodium picosulfate alone, embryofetal toxicity has been observed in rats and rabbits at very high doses (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).